SCHEDULE: Redmile Group Discloses 5.6% Stake in Zymeworks
Beneficial Ownership Disclosure
Redmile Group, LLC and its principal Jeremy C. Green have disclosed a 5.6% beneficial ownership stake in Zymeworks Inc. common stock.
Summary
- Redmile Group, LLC, an investment manager, and its principal, Jeremy C. Green, collectively reported beneficial ownership of 4,150,627 shares of Zymeworks Inc. common stock.
- This ownership represents 5.6% of Zymeworks Inc.'s outstanding common stock.
- The percentage is based on 74,844,505 shares of common stock outstanding as of June 27, 2025, as reported by Zymeworks Inc. in its Form 8-K.
- Redmile Biopharma Investments III, L.P., one of the private investment vehicles managed by Redmile Group, LLC, holds 3,470,727 shares, representing 4.6% of the class.
- The reported securities are held by various private investment vehicles managed by Redmile Group, LLC, with shared voting and dispositive power.
- Redmile Group, LLC and Jeremy C. Green disclaim beneficial ownership of these shares, except to the extent of their pecuniary interest.
Sentiment
Score: 7
Explanation: The filing itself is a neutral, factual disclosure. However, the presence of a significant ownership stake by a specialized institutional investor like Redmile Group can be interpreted as a positive signal of confidence in the company's value or future prospects, hence a slightly positive sentiment score.
Positives
- A significant beneficial ownership stake by an institutional investor like Redmile Group, LLC, may signal confidence in Zymeworks Inc.'s long-term prospects.
Negatives
- NA
Risks
- The filing itself does not detail specific risks related to Zymeworks Inc.'s operations or financial performance, as it is a beneficial ownership disclosure.
Future Outlook
This filing is a disclosure of beneficial ownership and does not contain forward-looking statements or guidance from Zymeworks Inc. or the reporting persons regarding the issuer's future performance.
Industry Context
Zymeworks Inc. operates in the biopharmaceutical industry. The disclosure of a significant stake by Redmile Group, a healthcare-focused investment firm, is a common occurrence in the biotech sector, where specialized funds often take substantial positions in companies developing novel therapies.
Stakeholder Impact
- Shareholders: Provides transparency regarding significant institutional ownership, which can influence market perception and trading activity.
- Company Management: Awareness of a significant shareholder may influence strategic decisions, though the filing states the shares are not held for the purpose of changing or influencing control.
Key Dates
| Date | Description |
|---|---|
| 06/27/2025 | Date Zymeworks Inc. reported 74,844,505 shares outstanding in its Form 8-K. |
| 06/30/2025 | Date of event which requires the filing of this statement (reporting period end date). |
| 08/14/2025 | Date the Schedule 13G Amendment No. 5 was signed and filed. |
Keywords
Zymeworks Inc., Redmile Group, Beneficial Ownership, Schedule 13G, Common Stock, Institutional Investor, Biopharma, Investment Management
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.